Aptose Biosciences Company Profile (NASDAQ:APTO)

Analyst Ratings

Consensus Ratings for Aptose Biosciences (NASDAQ:APTO) (?)
Ratings Breakdown: 4 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $13.75 (445.63% upside)

Analysts' Ratings History for Aptose Biosciences (NASDAQ:APTO)
Show:
DateFirmActionRatingPrice TargetActions
6/25/2016Royal Bank Of CanadaReiterated RatingOutperform$23.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/13/2016Roth CapitalUpgradeNeutral -> Buy$4.00 -> $8.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/9/2016Canaccord GenuityReiterated RatingBuy$7.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/9/2016Oppenheimer Holdings Inc.Reiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/30/2014 forward)

Earnings

Earnings History for Aptose Biosciences (NASDAQ:APTO)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
3/29/2016Q415($0.28)($0.38)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/10/2015Q315($0.33)($0.27)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/4/2015Q215($0.36)($0.28)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/4/2015($0.31)($0.31)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Aptose Biosciences (NASDAQ:APTO)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20162($0.30)($0.29)($0.30)
Q2 20162($0.32)($0.31)($0.32)
Q3 20162($0.32)($0.24)($0.28)
Q4 20162($0.34)($0.26)($0.30)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Aptose Biosciences (NASDAQ:APTO)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Aptose Biosciences (NASDAQ:APTO)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Latest Headlines for Aptose Biosciences (NASDAQ:APTO)
DateHeadline
07/29/16 02:33 PMProstate Cancer Pipeline Market 2016 Review Covering 257 Companies - Yahoo Finance
07/29/16 02:33 PMAptose Biosciences, Inc. (APTO) Updated Price Targets - FTSE News
07/28/16 11:15 AMDetailed examination of the non small cell lung cancer pipeline products, key players involved and enlists all their ... - WhaTech
07/19/16 02:32 PMAptose Biosciences Incorporated (NASDAQ:APTO) Shorted Shares Increased By 10.89% - Press Telegraph
07/17/16 02:29 PMAptose Biosciences, Inc. (APTO) Broker Price Targets For The Coming Week - Fiscal Standard
07/16/16 02:31 PMAptose Biosciences Incorporated (NASDAQ:APTO) Shorted Shares Increased By 13.51% - Consumer Eagle
07/13/16 02:34 PMAptose Biosciences Incorporated (NASDAQ:APTO) Sellers Increased By 13.51% Their Shorts - Consumer Eagle
07/08/16 02:33 PMCould Aptose Biosciences Inc Change Direction After Today's Huge Decline? - Engelwood Daily
07/06/16 02:33 PMBroker Outlook For Aptose Biosciences, Inc. (APTO) - Fiscal Standard
07/04/16 02:31 PMBroker Outlook For The Week Ahead Aptose Biosciences, Inc. (APTO) - Fiscal Standard
07/01/16 02:33 PMNew Broker Ratings For Aptose Biosciences, Inc. (APTO) - FTSE News
06/29/16 02:31 PMAptose Biosciences, Inc. (APTO) Current Analyst Ratings - Fiscal Standard
06/22/16 07:19 AMAptose Biosciences Announces Results of Annual Meeting of Shareholders - GlobeNewswire (press release)
06/21/16 03:19 PMAptose Biosciences Announces Results of Annual Meeting of Shareholders - [at noodls] - SAN DIEGO and TORONTO, June 21, 2016 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (NASDAQ:APTO) (TSX:APS) ('Aptose' or the 'Company') today announced the voting results from the Company's annual meeting ...
06/21/16 02:29 PMAptose Biosciences Provides Corporate Update in Advance of Annual Meeting of Shareholders - GlobeNewswire (press release)
06/21/16 02:29 PMForm 6-K Aptose Biosciences Inc. For: Jun 21 - StreetInsider.com
06/21/16 07:18 AMAptose Biosciences Provides Corporate Update in Advance of Annual Meeting of Shareholders - Nasdaq
06/21/16 07:00 AMAptose Biosciences Provides Corporate Update in Advance of Annual Meeting of Shareholders - [GlobeNewswire] - SAN DIEGO and TORONTO, June 21, 2016-- Aptose Biosciences Inc. today provided a corporate update in advance of the Company’ s Annual General Meeting of shareholders to be held today at 10:00 AM ET in Toronto, ...
06/19/16 07:17 AMAptose Biosciences, Inc. (APTO) Analyst Price Targets For The Coming Week - Fiscal Standard
06/13/16 02:43 PMAptose Upgraded To Buy At Roth, Price Target Doubled
06/13/16 10:37 AMAPTO-253
06/13/16 10:37 AM6 Largest Price Target Changes For Monday
06/13/16 05:16 AMAptose Biosciences upgraded by ROTH Capital -
06/11/16 10:44 AMAptose, CrystalGenomics ink global option & license pact for non-covalent BTK/ FLT3/AURK inhibitor
06/08/16 11:00 AMAptose Biosciences and CrystalGenomics Announce Exclusive Agreement for Non-Covalent BTK / FLT3 / AURK Inhibitor - GlobeNewswire (press release)
06/08/16 11:00 AMBRIEF-Aptose Biosciences, CrystalGenomics sign cancer drug deal - Reuters
06/08/16 07:18 AMAptose Biosciences and CrystalGenomics Announce Exclusive Agreement for Non-Covalent BTK / FLT3 / AURK Inhibitor - [at noodls] - TORONTO and SEOUL, South Korea, June 08, 2016 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (NASDAQ:APTO) (TSX:APS) and CrystalGenomics, Inc. (KOSDAQ:083790) today announced an exclusive global option and ...
06/08/16 07:15 AM8:15 am Aptose Biosciences and CrystalGenomics announce exclusive global option and license agreement focused on the development of CG026806 -
06/01/16 10:57 AMAptose Biosciences, Inc. (NASDAQ:APTO) Stock Update & Estimates - Stock Tick Tock - Aptose Biosciences, Inc. (NASDAQ:APTO) Stock Update & EstimatesStock Tick TockThe consensus on Wall Street is expecting Aptose Biosciences, Inc. (NASDAQ:APTO) to post earnings of $-0.3 per share when the firm next reports it's fiscal quarterly results. According to the latest information available the report will likely be ...and more »
06/01/16 10:57 AMBuy, Sell Or Hold Rating For Aptose Biosciences, Inc. (APTO)? - Share Trading News - Buy, Sell Or Hold Rating For Aptose Biosciences, Inc. (APTO)?Share Trading News03/30/2016 – Aptose Biosciences, Inc. had its “outperform” rating reiterated by analysts at RBC Capital. They now have a USD 18 price target on the stock. 11/23/2015 – Aptose Biosciences, Inc. had its “outperform” rating reiterated by analysts at ...
05/26/16 10:46 AMLatest Analyst Ratings For Aptose Biosciences, Inc. (APTO) - Share Trading News - Latest Analyst Ratings For Aptose Biosciences, Inc. (APTO)Share Trading News03/30/2016 – Aptose Biosciences, Inc. had its “outperform” rating reiterated by analysts at RBC Capital. They now have a USD 18 price target on the stock. 11/23/2015 – Aptose Biosciences, Inc. had its “outperform” rating reiterated by analysts at ...
03/14/16 07:00 AMAptose To Release Fourth Quarter and Year End December 31, 2015 Financial Results and Hold Conference Call on March 29, 2016 - [GlobeNewswire] - SAN DIEGO and TORONTO, March 14, 2016-- Aptose Biosciences Inc., a clinical-stage company developing new therapeutics and molecular diagnostics that target the underlying mechanisms of cancer, will release ...
03/03/16 04:00 PMAptose to Participate in Upcoming Investor Conferences - [GlobeNewswire] - SAN DIEGO and TORONTO, March 03, 2016-- Aptose Biosciences Inc., a clinical-stage company developing new therapeutics and molecular diagnostics that target the underlying mechanisms of cancer, today announced ...
02/18/16 04:00 PMAptose to Present at the 2016 RBC Capital Markets Global Healthcare Conference - [GlobeNewswire] - SAN DIEGO and TORONTO, Feb. 18, 2016-- Aptose Biosciences Inc., a clinical-stage company developing new therapeutics and molecular diagnostics that target the underlying mechanisms of cancer, today announced ...
02/14/16 01:30 PMAptose Biosciences Incorporated (NASDAQ:APTO) Shorted Shares Increased 4.99% After Market Selling - fdanewsalert.com - Aptose Biosciences Incorporated (NASDAQ:APTO) Shorted Shares Increased 4.99% After Market Sellingfdanewsalert.comThe short interest to Aptose Biosciences Incorporated's float is 0.48%. The stock is down 1.24% or $0.03 after the news, hitting $2.39 per share. About 655 shares traded hands. Aptose Biosciences Inc (NASDAQ:APTO) has declined 48.62% since July 9, 2015 ...and more »
02/07/16 01:06 PMAptose Biosciences Incorporated (NASDAQ:APTO) Shorted Shares Increased 21.15% After Market Selling - fdanewsalert.com - Aptose Biosciences Incorporated (NASDAQ:APTO) Shorted Shares Increased 21.15% After Market Sellingfdanewsalert.comThe short interest to Aptose Biosciences Incorporated's float is 0.46%. The stock is down 9.46% or $0.28 after the news, hitting $2.68 per share. About 21,615 shares traded hands or 61.54% up from the average. Aptose Biosciences Inc (NASDAQ:APTO) has ...and more »
02/03/16 01:02 PMIt Seems Aptose Biosciences Inc Will Go Up. Have Another Big Increase - WallStreet.org - It Seems Aptose Biosciences Inc Will Go Up. Have Another Big IncreaseWallStreet.orgAptose Biosciences Inc. is a clinical stage biotechnology company. The company has a market cap of $48.79 million. The Firm is engaged in development of targeted therapies addressing unmet medical needs in oncology. It currently has negative earnings.
01/27/16 12:20 PMSentiment And Earnings Update For Aptose Biosciences, Inc. (NASDAQ:APTO) - Investor Newswire - Sentiment And Earnings Update For Aptose Biosciences, Inc. (NASDAQ:APTO)Investor NewswireZacks Research aggregated analysts opinion on Aptose Biosciences, Inc. (NASDAQ:APTO) and assigned an average broker rating of 2. The research company rating methodology takes into account the research brokerage firms' forecasts on a scale of one to ...and more »
01/22/16 06:59 PMWhy Aptose Biosciences, Inc. (NASDAQ:APTO) Stock Is In The Spotlight? - Stocks Daily - Why Aptose Biosciences, Inc. (NASDAQ:APTO) Stock Is In The Spotlight?Stocks DailyAptose Biosciences, Inc. (NASDAQ:APTO) have been getting positive report from the sell-side analysts. Zacks published the results of recently conducted poll wherein the company cherished a mean rating of 2 rating. To make it clearer, this number is ...and more »
01/20/16 11:57 AMCytoDyn Appoints Denis R. Burger, Ph.D., as Chief Science Officer - CNNMoney - CytoDyn Appoints Denis R. Burger, Ph.D., as Chief Science OfficerCNNMoneyDr. Burger is currently lead director of Aptose Biosciences Inc., a cancer therapeutics, NASDAQ-listed company. Dr. Burger co-founded Trinity Biotech, a NASDAQ-listed diagnostic company, in June 1992, served as its Chairman from June 1992 to May 1995, ...and more »
01/20/16 11:57 AMCytoDyn Appoints Denis R. Burger, Ph.D., As Chief Science Officer - Dr. Burger is currently lead director of Aptose Biosciences Inc., a cancer therapeutics, NASDAQ-listed company. Dr. Burger co-founded Trinity Biotech, a NASDAQ-listed diagnostic company, in June 1992, served as its Chairman from June 1992 to May 1995 ...
01/19/16 06:41 PMAnalysts Issue Earnings Forecast For Aptose Biosciences, Inc. (NASDAQ:APTO) - Investor Newswire - Analysts Issue Earnings Forecast For Aptose Biosciences, Inc. (NASDAQ:APTO)Investor NewswireAccording to analysts surveyed by Zacks Research, Aptose Biosciences, Inc. (NASDAQ:APTO) is expected to post earnings of $-0.22 per share for its most recent quarter. The company is set to release its earnings around 2016-03-01. Since the same set of ...and more »
11/10/15 03:05 PMAptose Biosciences Reports Results for the Third Quarter Ended September 30, 2015 - [GlobeNewswire] - SAN DIEGO and TORONTO -- Aptose Biosciences Inc. (NASDAQ:APTO) a clinical-stage company developing new therapeutics and molecular diagnostics that target the underlying mechanisms of cancer, today reported ...
11/10/15 07:30 AMAptose Biosciences Announces Collaborations for New Multi-Targeting Epigenetic Therapeutic Agents - [GlobeNewswire] - Moffitt Cancer Center Grants Aptose Exclusive Global Rights to Highly Potent Multi-Targeting Epigenetic Inhibitors
11/05/15 08:15 AMBeat AML & Aptose Biosciences Present Data for APTO-253 at the 57th American Society of Hematology (ASH) Annual Meeting - [GlobeNewswire] - SAN DIEGO and TORONTO -- Aptose Biosciences Inc. (NASDAQ:APTO) , a clinical-stage company developing targeted agents and molecular diagnostics to treat the underlying mechanisms of cancer, today announced ...
11/05/15 07:00 AMAptose Biosciences to Host Third Quarter Ended September 30, 2015 Financial Results Conference Call and Webcast - [GlobeNewswire] - SAN DIEGO and TORONTO -- Aptose Biosciences Inc. (Aptose) (NASDAQ:APTO) , a clinical-stage company developing new therapeutics and molecular diagnostics that target the underlying mechanisms of cancer, ...
10/15/15 04:00 PMAptose Biosciences to Present at the 2015 BIO Investor Forum - [GlobeNewswire] - SAN DIEGO and TORONTO -- Aptose Biosciences Inc. (NASDAQ:APTO) , a clinical-stage company developing new therapeutics and molecular diagnostics that target the underlying mechanisms of cancer, today announced ...
08/10/15 08:30 AMNew Strong Buy Stocks for August 10th - Tale of the Tape -
06/10/15 04:00 PMAptose Biosciences announces results of annual and special meeting of shareholders - [CNW Group] - Aptose Biosciences announces results of annual and special meeting of shareholders
06/02/15 01:00 PMAptose Biosciences Granted Orphan Drug Designation by the U.S. FDA for APTO-253 in Acute Myeloid Leukemia - [CNW Group] - Aptose Biosciences Granted Orphan Drug Designation by the U.S. FDA for APTO-253 in Acute Myeloid Leukemia

Social

About Aptose Biosciences

Aptose Biosciences logoAptose Biosciences Inc. (Aptose) is a clinical stage biotechnology company. The Company is engaged in development of targeted therapies addressing unmet medical needs in oncology. The Company has product candidates in two classes of anti-cancer therapies: Small molecule program and large molecule program. The Company's group of small molecule compounds includes lead drug APTO-253 in acute myeloid leukemia (AML), myelodysplastic syndromes (MDS) and other hematologic malignancies. APTO-253 is an inducer of the Kruppel-like factor 4 gene (the Klf4 Gene) for patients with advanced hematologic malignancies. Additionally, the Company has a preclinical small molecule program, APTO-500, targeting maternal embryonic leucine zipper kinase (MELK) for the treatment of various cancers. The Company's large molecule program includes a molecule to target specific cell-surface receptors expressed in certain cancers expressing the Interleukin-17E receptor (IL-17ER).

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: N/A
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: APTO
  • CUSIP:
Key Metrics:
  • Previous Close: $2.50
  • 50 Day Moving Average: $2.54
  • 200 Day Moving Average: $2.63
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $30.65M
  • Beta: 1.35
  • Current Year EPS Consensus Estimate: $-1.13 EPS
  • Next Year EPS Consensus Estimate: $-1.11 EPS
Additional Links:
Aptose Biosciences (NASDAQ:APTO) Chart for Saturday, July, 30, 2016